Screener
Avalo Therapeutics AVTX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's debt-to-equity?
- Avalo Therapeutics (AVTX) reported debt-to-equity of 0× in Q2 2026.
- How has Avalo Therapeutics's debt-to-equity changed year-over-year?
- Avalo Therapeutics's debt-to-equity decreased by 92.3% year-over-year, from 0× to 0×.
- What is the long-term trend for Avalo Therapeutics's debt-to-equity?
- Over 4 years (2020 to 2025), Avalo Therapeutics's debt-to-equity has grown at a -45.9% compound annual growth rate (CAGR), from 0.1× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Avalo Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude